Proprietary Telomere Platform Life Length specializes in telomere diagnostics using their patented TAT platform, enabling precise telomere length measurement at the single-cell level across blood, cell culture, and tissue samples. This offers a unique value proposition for oncology, aging research, and personalized medicine clients seeking early biomarker insights.

Early Cancer Biomarker They recently developed an early detection biomarker for prostate cancer validated by AEMPS in Europe and CMS in the United States, with current availability in Europe. This presents a direct sales angle to oncology clinics, pathology labs, and CROs seeking validated diagnostic tools.

Regulatory Certifications Holdings include ISO 15189, CLIA, ISO 13485, AEMPS, plus U.S. state licenses (California, Rhode Island, Maryland, Pennsylvania). These certifications support cross-border selling to clinical laboratories and CROs requiring compliant diagnostic workflows and quality management.

Global CRO & Biotech Fit Serving leading clients in over 30 countries with in vivo and in vitro assays positions Life Length well for partnerships with international CROs, pharma R&D programs, and academic collaborations seeking telomere-based assays for diagnosis, prognosis, and preventive medicine.

Growth & Funding Signals Recent financing plus a substantial revenue range indicate scalability and market interest in telomere diagnostics. This suggests opportunities for tiered offerings, pilot programs, and strategic alliances with healthcare providers and biotechnology investors seeking expansion in diagnostic capabilities.